Roivant Sciences Ltd’s filing revealed that its President & Immunovant CEO Venker Eric unloaded Company’s shares for reported $1.15 million on Jul 21 ’25. In the deal valued at $11.52 per share,100,000 shares were sold. As a result of this transaction, Venker Eric now holds 1,462,223 shares worth roughly $16.83 million.
Then, Venker Eric bought 100,000 shares, generating $1,151,942 in total proceeds.
Before that, Venker Eric sold 100,000 shares. Roivant Sciences Ltd shares valued at $1,145,000 were divested by the President & COO at a price of $11.45 per share. As a result of the transaction, Venker Eric now holds 1,462,223 shares, worth roughly $16.83 million.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid February with a ‘”an Outperform”‘ rating. Piper Sandler began covering ROIV with “an Overweight” recommendation on January 05, 2024. Deutsche Bank started covering the stock on December 12, 2023. It rated ROIV as “a Buy”.
Price Performance Review of ROIV
On Monday, Roivant Sciences Ltd [NASDAQ:ROIV] saw its stock jump 1.77% to $11.51. Over the last five days, the stock has gained 1.41%. Roivant Sciences Ltd shares have risen nearly 6.08% since the year began. Nevertheless, the stocks have fallen -2.70% over the past one year.
How much short interest is there in Roivant Sciences Ltd?
A steep rise in short interest was recorded in Roivant Sciences Ltd stocks on 2025-07-15, dropping by -2.71 million shares to a total of 42.36 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 45.06 million shares. There was a decline of -6.39%, which implies that there is a negative sentiment for the stock.
